<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; and</title>
	<atom:link href="http://www.tapanray.in/tag/and/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Two Paintings on the Same Canvas: &#8216;Truth About Drug Companies&#8217; and &#8216;Protecting Access to Medicines&#8217;</title>
		<link>http://www.tapanray.in/two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines</link>
		<comments>http://www.tapanray.in/two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines/#comments</comments>
		<pubDate>Mon, 13 May 2013 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[about]]></category>
		<category><![CDATA[About It.]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Angell]]></category>
		<category><![CDATA[book]]></category>
		<category><![CDATA[canvas]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Deceive]]></category>
		<category><![CDATA[do]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Editor]]></category>
		<category><![CDATA[England]]></category>
		<category><![CDATA[Forbes]]></category>
		<category><![CDATA[former]]></category>
		<category><![CDATA[foundation]]></category>
		<category><![CDATA[Harvard]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[her]]></category>
		<category><![CDATA[How]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[journal]]></category>
		<category><![CDATA[leading]]></category>
		<category><![CDATA[M.D.faculty]]></category>
		<category><![CDATA[Marcia]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NEJM]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[paintings]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHFI]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[protecting]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy]]></category>
		<category><![CDATA[same]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[Srinath]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[TheTruth]]></category>
		<category><![CDATA[they]]></category>
		<category><![CDATA[titled]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[What to]]></category>
		<category><![CDATA[world’s]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2280</guid>
		<description><![CDATA[As the saying goes, &#8220;Great people think alike&#8221;, many thought leaders of very high credibility across the globe, seem to think almost in similar lines when it comes to improving access to medicines for a large section of the global &#8230; <a href="http://www.tapanray.in/two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>To Curb Pharma Marketing Malpractices in India Who Bells the Cat?</title>
		<link>http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat</link>
		<comments>http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/#comments</comments>
		<pubDate>Mon, 18 Mar 2013 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Australia]]></category>
		<category><![CDATA[bribe]]></category>
		<category><![CDATA[cat]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[curb]]></category>
		<category><![CDATA[curbing]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[E&Y]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HHS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[indictment]]></category>
		<category><![CDATA[inertia]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[intriguing]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[Jyoti]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[Mirdha]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[mouse]]></category>
		<category><![CDATA[Netherlands]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[Planning]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[slovakia]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Sunshine]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2050</guid>
		<description><![CDATA[Bribing doctors by the pharmaceutical companies directly or indirectly, as reported frequently by the media all over the world, including India, to prescribe their respective brand of drugs has now reached an alarming proportion, jeopardizing patients’ interest, seriously more than &#8230; <a href="http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients”: Exploring the book to be released in the Indian context</title>
		<link>http://www.tapanray.in/bad-pharma-how-drug-companies-mislead-doctors-and-harm-patients-exploring-the-book-to-be-released-in-the-indian-context/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=bad-pharma-how-drug-companies-mislead-doctors-and-harm-patients-exploring-the-book-to-be-released-in-the-indian-context</link>
		<comments>http://www.tapanray.in/bad-pharma-how-drug-companies-mislead-doctors-and-harm-patients-exploring-the-book-to-be-released-in-the-indian-context/#comments</comments>
		<pubDate>Mon, 15 Oct 2012 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Bad]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[book]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[context]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[Exploring]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Harm]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[How]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Mislead]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[released]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1081</guid>
		<description><![CDATA[The title of today’s article could make some of the readers uncomfortable and angry, just as what I experienced while writing the same, being a long time follower and student of the pharmaceutical industry, both global and local. Ethical business &#8230; <a href="http://www.tapanray.in/bad-pharma-how-drug-companies-mislead-doctors-and-harm-patients-exploring-the-book-to-be-released-in-the-indian-context/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/bad-pharma-how-drug-companies-mislead-doctors-and-harm-patients-exploring-the-book-to-be-released-in-the-indian-context/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Supreme Court Intervened…But ‘Price Control’ needs striking a right balance between ‘Affordability’ and ‘Availability’ of medicines for Patients’ Sake</title>
		<link>http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients</link>
		<comments>http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/#comments</comments>
		<pubDate>Mon, 08 Oct 2012 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Availability]]></category>
		<category><![CDATA[balance]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[But]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intervened]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[medicines for Patients’ Sake]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[striking]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1084</guid>
		<description><![CDATA[On October 3, 2012, the Supreme Court bench of Justice GS Singhvi and Justice SJ Mukhopadhayareportedly asked the government not to disturb the existing price control mechanism while including all medicines featuring  in the National List of Essential Medicines 2011 (NLEM &#8230; <a href="http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma industry requires striking a right balance between ethical obligations to shareholders and ethical obligations to patients</title>
		<link>http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients</link>
		<comments>http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/#comments</comments>
		<pubDate>Mon, 24 Sep 2012 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[balance]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[obligations]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[requires]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[shareholders]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[striking]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=6</guid>
		<description><![CDATA[On September 15, 2012, while delivering his keynote address in a pharmaceutical industry function, Dr. Sam Pitroda, the Chicago based Indian, creator of the telecom revolution in India and the Advisor to the Prime Minister on Public Information, Infrastructure &#38; &#8230; <a href="http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nutraceuticals with Therapeutic Claims: A Vulnerable Growing Bubble Protected by Faith and Hope of Patients</title>
		<link>http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients</link>
		<comments>http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/#comments</comments>
		<pubDate>Mon, 27 Aug 2012 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Bubble]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[Claims]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[Faith]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hope]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Protected]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[Vulnerable]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=45</guid>
		<description><![CDATA[Today a growing number of particularly the aging population wants to live a healthy life without consuming much of chemical drugs, which in turn is becoming a key growth driver for nutraceutical products across the world. Further, increasing interest towards &#8230; <a href="http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>e-Patients: Quality and Cost Empowered Patients Will Help Reducing Healthcare Costs in India Significantly</title>
		<link>http://www.tapanray.in/e-patients-quality-and-cost-empowered-patients-will-help-reducing-healthcare-costs-in-india-significantly/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=e-patients-quality-and-cost-empowered-patients-will-help-reducing-healthcare-costs-in-india-significantly</link>
		<comments>http://www.tapanray.in/e-patients-quality-and-cost-empowered-patients-will-help-reducing-healthcare-costs-in-india-significantly/#comments</comments>
		<pubDate>Mon, 30 Jul 2012 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[Empowered]]></category>
		<category><![CDATA[ePatients]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[help]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India Significantly]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reducing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Will]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=59</guid>
		<description><![CDATA[Currently many important stakeholders of the healthcare industry, reportedly, are using or rather exploiting the individual patients not just to derive petty commercials gains, but also for quite significant strategic commercial advantages, mainly due to ignorance or helplessness of a &#8230; <a href="http://www.tapanray.in/e-patients-quality-and-cost-empowered-patients-will-help-reducing-healthcare-costs-in-india-significantly/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/e-patients-quality-and-cost-empowered-patients-will-help-reducing-healthcare-costs-in-india-significantly/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Counterfeit Drugs and ACTA: Should the global menace related to &#8216;Public Health and Safety&#8217; be mixed-up with Intellectual Property Rights?</title>
		<link>http://www.tapanray.in/counterfeit-drugs-and-acta-should-the-global-menace-related-to-public-health-and-safety-be-mixed-up-with-intellectual-property-rights/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=counterfeit-drugs-and-acta-should-the-global-menace-related-to-public-health-and-safety-be-mixed-up-with-intellectual-property-rights</link>
		<comments>http://www.tapanray.in/counterfeit-drugs-and-acta-should-the-global-menace-related-to-public-health-and-safety-be-mixed-up-with-intellectual-property-rights/#comments</comments>
		<pubDate>Mon, 02 Jul 2012 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ACTA]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[menace]]></category>
		<category><![CDATA[mixed-up]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[related]]></category>
		<category><![CDATA[Rights]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Should]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=72</guid>
		<description><![CDATA[Here in this article, I am talking about drugs or medicines, which you may ultimately land up into buying, quite innocently though, against your doctor’s prescriptions, without having an inkling that these drugs can push you into serious health hazards, &#8230; <a href="http://www.tapanray.in/counterfeit-drugs-and-acta-should-the-global-menace-related-to-public-health-and-safety-be-mixed-up-with-intellectual-property-rights/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/counterfeit-drugs-and-acta-should-the-global-menace-related-to-public-health-and-safety-be-mixed-up-with-intellectual-property-rights/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Kaleidoscope of Drug Price Control Spanning Across the World and Its Relevance to India</title>
		<link>http://www.tapanray.in/a-kaleidoscope-of-drug-price-control-spanning-across-the-world-and-its-relevance-to-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-kaleidoscope-of-drug-price-control-spanning-across-the-world-and-its-relevance-to-india</link>
		<comments>http://www.tapanray.in/a-kaleidoscope-of-drug-price-control-spanning-across-the-world-and-its-relevance-to-india/#comments</comments>
		<pubDate>Mon, 25 Jun 2012 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Across]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[its]]></category>
		<category><![CDATA[Kaleidoscope]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[Spanning]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=76</guid>
		<description><![CDATA[How much to charge for a drug? While there is no single or only right way to arrive at the price of a medicine, how much the pharmaceutical manufacturers will charge for a drug still remains an important, yet complex &#8230; <a href="http://www.tapanray.in/a-kaleidoscope-of-drug-price-control-spanning-across-the-world-and-its-relevance-to-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-kaleidoscope-of-drug-price-control-spanning-across-the-world-and-its-relevance-to-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Indian Drug Regulator Accords Primacy to Pharma Industry Instead of Safegurding Public Health and Safety” – Parliamentary Committee</title>
		<link>http://www.tapanray.in/indian-drug-regulator-accords-primacy-to-pharma-industry-instead-of-safegurding-public-health-and-safety-parliamentary-committee/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-drug-regulator-accords-primacy-to-pharma-industry-instead-of-safegurding-public-health-and-safety-parliamentary-committee</link>
		<comments>http://www.tapanray.in/indian-drug-regulator-accords-primacy-to-pharma-industry-instead-of-safegurding-public-health-and-safety-parliamentary-committee/#comments</comments>
		<pubDate>Mon, 28 May 2012 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Accords]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Instead]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Primacy]]></category>
		<category><![CDATA[PSC]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[Safegurding]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=88</guid>
		<description><![CDATA[The Department Related Parliamentary Committee on Health and Family Welfare presented its 59th Report of 118 pages in total on the functioning of the Indian Drug Regulator &#8211; the Central Drug Standards Control Organization (CDSCO) in both the houses of &#8230; <a href="http://www.tapanray.in/indian-drug-regulator-accords-primacy-to-pharma-industry-instead-of-safegurding-public-health-and-safety-parliamentary-committee/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-drug-regulator-accords-primacy-to-pharma-industry-instead-of-safegurding-public-health-and-safety-parliamentary-committee/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
